WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products, today announced that sanofi-aventis has initiated a ...
– ImmunoGen anticancer compound shows favorable tolerability and evidence of activity, with dose escalation continuing – WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a ...
ImmunoGen, Inc. lead drug (Elahere) recently gained accelerated approval to treat patients afflicted by platinum-resistant ovarian cancers with the high FRA expression. The Q1 earnings report showed ...
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that 11 posters ...
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN) a biotechnology company developing targeted cancer therapeutics using its proprietary antibody-drug conjugate (ADC) technology, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback